SCHEMBL3746153

SCHEMBL3746153

CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CC(Cc1ccc(-c2ccccn2)cc1)NC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
CTSD P07339 2/20 0.54
UGT1A1 P22309 2/20 0.51
MLNR O43193 1/20 0.51
NR1I2 O75469 1/20 0.51
SLCO2B1 O94956 1/20 0.51
ABCB11 O95342 1/20 0.51
ABCB1 P08183 1/20 0.51
CCKAR P32238 1/20 0.51
OPRK1 P41145 1/20 0.51
GHSR Q92847 1/20 0.51
SLCO1B3 Q9NPD5 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
SLCO1B1 Q9Y6L6 1/20 0.51
KLK5 Q9Y337 3/20 0.48
PSEN1 P49768 4/20 0.46
PSEN2 P49810 4/20 0.46
APH1B Q8WW43 4/20 0.46
NCSTN Q92542 4/20 0.46
APH1A Q96BI3 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748370 1.00 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3802932 1.00 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3746143 1.00 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3801029 0.96 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3801282 0.96 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3801276 0.96 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3801033 0.96 CYP3A4 (0.54) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL3797436 0.90 CYP3A4 (0.65) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL2438132 0.88 UGT1A1 (0.49) CYP3A4CTSDUGT1A1MLNRNR1I2
SCHEMBL2438930 0.87 CYP3A4 (0.46) CYP3A4CTSDUGT1A1MLNRNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140194349-A1 HIV Protease Inhibiting Compounds ABBVIE INC. (US) 2014-07-10 US disclosed
EP-2266971-A2 Hiv protease inhibiting compounds Abbott Laboratories (US) 2010-12-29 EP disclosed
US-7834043-B2 Prevent reproduct of aids virus ABBOTT LABORATORIES (US) 2010-11-16 US disclosed
US-20050148623-A1 Prevent reproduct of aids virus ABBVIE INC. 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148623-A1 Prevent reproduct of aids virus SERPINB1, PRSS1, SERPINA3 CYP3A4 481/4885CTSD 146/4885UGT1A1 1234/4885
US-20140194349-A1 HIV Protease Inhibiting Compounds SERPINB1, HPN, DNPEP CYP3A4 764/4885CTSD 84/4885UGT1A1 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.